Endocrinology

A new study from Duke University suggests combining weight loss counseling to group medical visits was noninferior to typical medication treatment for lowing HbA1c in diabetic patients.

A new study from the National Center for Global Health and Medicine in Japan has found thiazide use in diabetics with well-controlled blood pressure led to an increased risk of MACE, particularly stroke.

The rapid-acting insulin will now be used in infusion pumps to treat adults with Type 1 or Type 2 diabetes.

AstraZeneca announced approval of the SGLT2 inhibitor for the reduction of hospitalization for heart failure in type 2 diabetes patients in a release on Monday.

Researchers writing in the New England Journal of Medicine report that a combination treatment of ticagrelor and aspirin leads to improved cardiovascular disease outcomes in patients with stable coronary artery disease and diabetes mellitus.

A comprehensive systematic review and meta-analysis of 36 randomized clinical trials shows that using activity trackers produces some health benefit, but primarily when combined with coaching.

Hepatitis C virus infections are strongly linked to type 2 diabetes, according to new research.

The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.

Adults with early type two diabetes and elevated cardiovascular risk may be able to safely take linagliptin or sulfonylurea (glimepiride) without increasing their risk of cardiovascular events, researchers report in JAMA.

A recent study of primary practices in England found Asian patients were 15% less likely to be prescribed insulin, while black patients were half as likely to be prescribed a GLP-1 agonist or SGLT2 inhibitor.

George Bakris, MD, professor of medicine at University of Chicago Medicine and member of CREDENCE steering committee, discusses the recent approval of canagliflozin and what it means for diabetic patients and their physicians.

African Americans are more greatly burdened by the cardiovascular condition and its common comorbidities. Are new therapies able to help?

A new study from the Harvard T.H. Chan School of Public Health found increasing consumption of sugary beverages, including 100% fruit juices, by half a serving per day could increase a person's risk of diabetes by 16%.

A recent study from the ACC Middle East Conference 2019 found patients with hypertension and type 2 diabetes who consume a high fiber diet had improvement in their blood pressure, cholesterol and fasting glucose.

In a review of chronic kidney disease, investigators suggest a variety of screening and risk reduction measures.

A recent study of pregnancies from the Quebec Pregnancy Cohort found use of antidepressants during pregnancy was linked to an increased rate of gestational diabetes mellitus in an analysis that included more than 200,000 women from 1998 to 2015.

Among adults with recently-diagnosed type 2 diabetes and elevated cardiovascular risk, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride treatment resulted in similar cardiovascular outcomes over a median 6.3 years.

The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes.

Image IQ:  A 60-year-old woman undergoing hemodialysis for chronic kidney disease developes a smooth plaque on her leg. What's  your diagnosis?

The diabetes management and adult health specialist reacts to the SGLT2 inhibitor's newest indication.

The SGLT2 inhibitor from Janssen has shown significant benefit for reducing progression to end-stage kidney disease, as well as risk for major adverse cardiovascular events.

Vanita Aroda, MD, of Brigham and Women's Hospital, discusses the impact of PIONEER trials and the implications the approval for oral semaglutide has on diabetes care.

A recent study into insulin use in adults 75 and older found insulin use was increased in those with worse health, indicating a lack of adherence to current guideline recommendations.

In new research published in the New England Journal of Medicine, investigators led by William Tamborlane, M.D., a Yale University pediatric endocrinologist, reported the efficacy of the GLP1 agonist liraglutide for children with type 2 diabetes. In this Q&A, Dr. Tamborlane discusses the importance of expanding treatment options.

The therapy becomes the first oral GLP-1 agonist approved for the treatment of A1C reduction.